RUNX1 and plasma cell myeloma: Interestingly, RUNX1 and RUNX3 interact with Ikaros family zinc finger protein 1 (IKZF1) and IKZF3 to prevent their lenalidomide-induced degradation, and inhibiting RUNX proteins enhances immunomodulatory imide drugs (IMiD) sensitivity in multiple myeloma, offering a promising strategy to overcome drug resistance (40).